As trading for November begins, Mizuho recommends a few stocks for investors to consider. The Dow Jones, S&P 500, and Nasdaq Composite have all registered gains, marking a shift from October's downturn.
According to CNBC, Mizuho's equity research team has put together its top buy-rated picks for November. The list includes new names like Coterra Energy Inc CTRA, Merck & Co. MRK, EyePoint Pharmaceuticals EYPT and Intuit INTU.
Despite a Wall Street average rating of "hold" for Coterra, Mizuho is bullish on the stock, which is already up about 14% this year. Analyst Nitin Kumar points to the company's potential upside and its peer-leading cash return framework as reasons for optimism.
See Also: Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase
Mizuho is also positive about Merck, despite a nearly 7% dip in its stock this year. Analyst Mara Goldstein cites the company's promising pharmaceutical pipeline as a key growth driver.
EyePoint Pharmaceuticals, whose shares have risen over 120% this year, is also on Mizuho's radar. Analyst Graig Suvannavejh highlights the company's focus on less frequently administered eye therapies as its unique selling point.
The last on the list, Intuit, is touted as a potential artificial-intelligence winner. Analyst Siti Panigrahi notes the company's defensible business model and its strong track record of growth.
The stocks of the four companies are anticipated to see further growth, with Mizuho's analysts offering optimistic projections for each.
The full list is below, along with the average rating via LSEG and the upside/downside to the average price target (%) via LSEG:
- Coterra Energy: Hold; 15.5
- Merck & Co: Buy; 20.9
- EyePoint Pharmaceuticals: Buy; 289.9
- Intuit: Buy, 13.5
- Mondelez International Inc MDLZ: Buy; 16.0
- DTE Energy Co DTE: Buy; 10.3
- Pentair PLC PNR: Buy; 20.4
- Omega Healthcare Investors Inc OHI: Hold; 8.1
- Amazon.com Inc AMZN: Buy; 24.4
- Nvidia Corp NVDA: Buy; 39.6
Read Next: This Week In Apple: iPhone 16 Expectations, Wall Street's Overreaction On Q4 Guidance And More
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
